​

Anebulo Pharmaceuticals (ANEB) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ANEB Stock Forecast

Anebulo Pharmaceuticals stock forecast is as follows: an average price target of $6.00 (represents a 270.37% upside from ANEB’s last price of $1.62) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

ANEB Price Target

The average price target for Anebulo Pharmaceuticals (ANEB) is $6.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 270.37% upside from ANEB's last price of $1.62.

ANEB Analyst Ratings

Buy

According to 1 Wall Street analysts, Anebulo Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ANEB stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Anebulo Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 18, 2023Boobalan PachaiyappanH.C. Wainwright$6.00$3.2783.49%270.37%

The latest Anebulo Pharmaceuticals stock forecast, released on Sep 18, 2023 by Boobalan Pachaiyappan from H.C. Wainwright, set a price target of $6.00, which represents a 83.49% increase from the stock price at the time of the forecast ($3.27), and a 270.37% increase from ANEB last price ($1.62).

Anebulo Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.62$1.62$1.62
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Anebulo Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Anebulo Pharmaceuticals's last price of $1.62. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 01, 2024BenchmarkSpeculative BuySpeculative BuyHold
Sep 18, 2023H.C. WainwrightBuyInitialise

Anebulo Pharmaceuticals's last stock rating was published by Benchmark on Oct 01, 2024. The company gave ANEB a "Speculative Buy" rating, the same as its previous rate.

Anebulo Pharmaceuticals Financial Forecast

Anebulo Pharmaceuticals Revenue Forecast

Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-----
Avg Forecast-----
High Forecast-----
Low Forecast-----
# Analysts-----
Surprise %-----

Anebulo Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ANEB's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Anebulo Pharmaceuticals EBITDA Forecast

Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----
EBITDA-----
Avg Forecast-----
High Forecast-----
Low Forecast-----
Surprise %-----

undefined analysts predict ANEB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Anebulo Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Anebulo Pharmaceuticals Net Income Forecast

Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----
Net Income-----
Avg Forecast$-2.07M$-2.07M$-2.07M$-1.30M$-2.84M
High Forecast$-2.07M$-2.07M$-2.07M$-1.30M$-2.84M
Low Forecast$-2.07M$-2.07M$-2.07M$-1.30M$-2.84M
Surprise %-----

Anebulo Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ANEB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Anebulo Pharmaceuticals SG&A Forecast

Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----
SG&A-----
Avg Forecast-----
High Forecast-----
Low Forecast-----
Surprise %-----

Anebulo Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ANEB last annual SG&A of $NaN (undefined).

Anebulo Pharmaceuticals EPS Forecast

Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----
EPS-----
Avg Forecast$-0.08$-0.08$-0.08$-0.05$-0.11
High Forecast$-0.08$-0.08$-0.08$-0.05$-0.11
Low Forecast$-0.08$-0.08$-0.08$-0.05$-0.11
Surprise %-----

According to undefined Wall Street analysts, Anebulo Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ANEB previous annual EPS of $NaN (undefined).

Anebulo Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
MOLNMolecular Partners$5.31$29.00446.14%Buy
AVTEAerovate Therapeutics$2.60$13.00400.00%Hold
PMVPPMV Pharmaceuticals$1.47$6.00308.16%Buy
OPTOpthea$3.63$14.00285.67%Buy
ANEBAnebulo Pharmaceuticals$1.62$6.00270.37%Buy
ANTXAN2 Therapeutics$1.36$5.00267.65%Buy
ACRVAcrivon Therapeutics$6.23$22.50261.16%Buy
ANABAnaptysBio$13.89$49.83258.75%Buy
ADAGAdagene$1.94$5.00157.73%Buy
MLYSMineralys Therapeutics$12.80$30.00134.38%Buy

ANEB Forecast FAQ

Is Anebulo Pharmaceuticals a good buy?

Yes, according to 1 Wall Street analysts, Anebulo Pharmaceuticals (ANEB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of ANEB's total ratings.

What is ANEB's price target?

Anebulo Pharmaceuticals (ANEB) average price target is $6 with a range of $6 to $6, implying a 270.37% from its last price of $1.62. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Anebulo Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for ANEB stock, the company can go up by 270.37% (from the last price of $1.62 to the average price target of $6), up by 270.37% based on the highest stock price target, and up by 270.37% based on the lowest stock price target.

Can Anebulo Pharmaceuticals stock reach $2?

ANEB's average twelve months analyst stock price target of $6 supports the claim that Anebulo Pharmaceuticals can reach $2 in the near future.

What are Anebulo Pharmaceuticals's analysts' financial forecasts?

Anebulo Pharmaceuticals's analysts financial forecasts for the fiscal year (Jun 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-2.84M (high $-2.84M, low $-2.84M), average SG&A $0 (high $0, low $0), and average EPS is $-0.11 (high $-0.11, low $-0.11). ANEB's analysts financial forecasts for the fiscal year (Jun 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-7.521M (high $-7.521M, low $-7.521M), average SG&A $0 (high $0, low $0), and average EPS is $-0.29 (high $-0.29, low $-0.29).